Addressing the gap in lung cancer screening

Lung cancer is the most deadly cancer.

More than any other cancer, lung cancer consistently takes more lives than the next top three cancers combined. Worldwide, 2.5 million new cases of lung cancer will be diagnosed in 2024 leading to over 1.8 million deaths. There are many challenges associated with identifying patients when the disease can be successfully treated. Unlike all other cancers, more patients are identified when the disease has already moved to distant sites. Once the disease has spread, treatment is generally palliative and long-term outcomes are very poor. In contrast, one can survive lung cancer if it is detected early enough.

Read the Full Article →

Previous
Previous

Hawkeye Bio Turns to IVD Strategy After Sharing Data on Protease-Based Lung Cancer Detection Tech

Next
Next

Description of an activity-based enzyme biosensor for lung cancer detection